This report was first published by Endpoints News. To see the original version, click here
Takeda’s ongoing restructuring has hit another Denali program as an eight-year-old partnership comes to an end between the two companies.
Takeda returned the full rights to a Denali drug called DNL593 ahead of a Phase 1/2 readout. The program is designed to treat frontotemporal dementia caused by mutations in the granulin gene, one of the most common genetic causes of the disease.
您已阅读23%（472字），剩余77%（1610字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。